Tirzepatide (GIP / GLP-1 dual agonist)

metabolic glycemic

Approved medicine for another condition in 8 of 9 markets tracked; in clinical trials in 1.

Evidence so far is from observational studies in people and animal studies.

Evidence map

each mark is a study; size shows participants; hover, tap or focus for details

main endpoints improvedno effectworsenedmixedobservationalanother intervention, contextsize not reported

Higher rows are closer to a person taking this. A case that rests only on the lower rows rests on animals or cells.

What each study measured

outlined square: the main (primary) endpoint

Harms reported

human studies

Where it is available

by regulator; select a market for its source

If you are tracking this yourself

measures the human studies used, by how repeatable they are

Repeatability is whether the same person measured twice gets the same number. It is not statistical significance. It informs study or protocol design only, never advice for a person.

What would change this picture

each study's own statement

Trials under way

Every study (4)

T5 Brouer 2026 Glucagon-like peptide-1 receptor agonists and tirzepatide are associated with reduced mortality, cardiovascular, and psychiatric risks in patients with hidradenitis suppurativa and type 2 diabetes and/or obesity: a retrospective cohort study doi:10.3389/fmed.2026.1909537
T5 Kitsunai 2026 Real-world clinical outcomes of tirzepatide administration in older patients with type 2 diabetes, with a focus on the risk of hypoglycemia and weight loss-related parameters doi:10.1507/endocrj.EJ26-0246
T5 Omura 2024 Tirzepatide and Glycemic Control Metrics Using Continuous Glucose Monitoring in Older Patients with Type 2 Diabetes Mellitus: An Observational Pilot Study doi:10.3390/geriatrics9020027
T3 M.D. 2026 Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice doi:10.1016/j.isci.2026.117174